Literature DB >> 21263248

miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas.

Valerio Del Vescovo1, Chiara Cantaloni, Alberto Cucino, Salvatore Girlando, Massimo Silvestri, Emma Bragantini, Silvia Fasanella, Lucia Veronica Cuorvo, Paolo Dalla Palma, Giulio Rossi, Mauro Papotti, Giuseppe Pelosi, Paolo Graziano, Alberto Cavazza, Michela Alessandra Denti, Mattia Barbareschi.   

Abstract

Accurate classification of nonsmall cell lung cancers is of paramount clinical relevance, as novel chemotherapeutic agents show different efficacy in adenocarcinomas (ADCs) compared with squamous cell carcinomas (SQCCs). Cyto and histomorphology may sometimes be insufficient for this distinction and immunohistochemistry may improve diagnostic accuracy. The measurement of miR-205 may be another tool for the distinction between ADC and SQCC. The aim of our study was to compare morphologic and immunohistochemical classification with the relative quantification of miR-205 and miR-21 insurgically resected and well-characterized lung tumors (25 ADCs, 24 SQCCs, 1 adenosquamous). The miR-21 relative levels were similar in SQCC and ADC, whereas the miR-205 relative levels were lower in ADC (P<0.0001). The miR-205 sample score value, determined according to Lebanony et al, was higher in ADC (range, 2.8 to 9.08) compared with SQCC (range, -4.17 to 2.445) (P<0.0001). Accordingly, 22 tumors were classified as ADC and 28 tumors as SQCC, although 8 cases (2 SQCCs and 6 ADCs) were in the range of "near cutoff values." Four cases classified as SQCC (according to the sample score method) corresponded to cases classified as ADC on the basis of morphoimmunohistochemical evaluation. In conclusion, the relative quantification of miR-205 and miR-21 seems to be a promising diagnostic tool. However, the molecular approach is still not completely satisfactory as it may misclassify a non-negligible percentage of cases. Therefore, it cannot be used as a substitute of accurate morphologic and immunophenotypical characterization of tumors, but could be used as an adjunctive diagnostic criterion in selected cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21263248     DOI: 10.1097/PAS.0b013e3182068171

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  24 in total

1.  Decision tree-based classifiers for lung cancer diagnosis and subtyping using TCGA miRNA expression data.

Authors:  Masih Sherafatian; Fateme Arjmand
Journal:  Oncol Lett       Date:  2019-06-10       Impact factor: 2.967

2.  Utility of p40 in the Differential Diagnosis of Small Round Blue Cell Tumors of the Sinonasal Tract.

Authors:  Matthew P Tilson; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2013-10-11

3.  MicroRNAs As Biomarkers For Clinical Features Of Lung Cancer.

Authors:  Roland Hubaux; Daiana D Becker-Santos; Katey S S Enfield; Stephen Lam; Wan L Lam; Victor D Martinez
Journal:  Metabolomics (Los Angel)       Date:  2012-03-21

4.  Use of p40 and p63 immunohistochemistry and human papillomavirus testing as ancillary tools for the recognition of head and neck sarcomatoid carcinoma and its distinction from benign and malignant mesenchymal processes.

Authors:  Justin A Bishop; Elizabeth A Montgomery; William H Westra
Journal:  Am J Surg Pathol       Date:  2014-02       Impact factor: 6.394

5.  miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes.

Authors:  Yong-Kui Zhang; Wang-Yu Zhu; Jian-Ying He; Dong-Dong Chen; Yan-Yan Huang; Han-Bo Le; Xiao-Guang Liu
Journal:  J Cancer Res Clin Oncol       Date:  2012-05-22       Impact factor: 4.553

6.  Applications of MicroRNAs in the Diagnosis and Prognosis of Lung Cancer.

Authors:  Jun Shen; Feng Jiang
Journal:  Expert Opin Med Diagn       Date:  2012-05

7.  Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing.

Authors:  Jie Ma; Kaiissar Mannoor; Lu Gao; Afang Tan; Maria A Guarnera; Min Zhan; Amol Shetty; Sanford A Stass; Lingxiao Xing; Feng Jiang
Journal:  Mol Oncol       Date:  2014-04-15       Impact factor: 6.603

8.  MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies.

Authors:  Santosh Patnaik; Reema Mallick; Eric Kannisto; Rohit Sharma; Wiam Bshara; Sai Yendamuri; Samjot Singh Dhillon
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

9.  Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients.

Authors:  Han-Bo Le; Wang-Yu Zhu; Dong-Dong Chen; Jian-Ying He; Yan-Yan Huang; Xiao-Guang Liu; Yong-Kui Zhang
Journal:  Med Oncol       Date:  2012-07-11       Impact factor: 3.064

Review 10.  Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis.

Authors:  Yue Yu; Jie He
Journal:  Front Med       Date:  2013-05-17       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.